Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.61 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.61 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.61 |
| ▸ | PPARA | Q07869 | 9/20 | 0.57 |
| ▸ | PPARG | P37231 | 8/20 | 0.57 |
| ▸ | PPARD | Q03181 | 2/20 | 0.57 |
| ▸ | CTSS | P25774 | 6/20 | 0.55 |
| ▸ | CTSK | P43235 | 5/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.54 |
| ▸ | CTSB | P07858 | 1/20 | 0.54 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.53 |
| ▸ | ITGAV | P06756 | 1/20 | 0.53 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.53 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.53 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7390262 | 1.00 | ACE (0.61) | ACEITGB3ITGA2BPPARAPPARG | |
| SCHEMBL2335345 | 0.93 | ACE (0.60) | ACEITGB3ITGA2BPPARAPPARG | |
| SCHEMBL9956011 | 0.93 | ACE (0.60) | ACEITGB3ITGA2BPPARAPPARG | |
| SCHEMBL2335337 | 0.93 | ACE (0.60) | ACEITGB3ITGA2BPPARAPPARG | |
| SCHEMBL7388523 | 0.90 | ACE (0.62) | ACEITGB3ITGA2BPPARAPPARG | |
| SCHEMBL7388520 | 0.90 | ACE (0.62) | ACEITGB3ITGA2BPPARAPPARG | |
| SCHEMBL3728971 | 0.90 | CTSS (0.58) | ACEITGB3ITGA2BPPARAPPARG | |
| SCHEMBL3728970 | 0.90 | CTSS (0.58) | ACEITGB3ITGA2BPPARAPPARG | |
| SCHEMBL12717412 | 0.89 | ACE (0.61) | ACEITGB3ITGA2BPPARAPPARG | |
| SCHEMBL9076659 | 0.89 | ITGB3 (0.51) | ACEITGB3ITGA2BPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4534524-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PeptiDream Inc. (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-7205435-B2 | Type B botulism toxin inhibitors | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2007-04-17 | — | — | US | disclosed |
| US-20040176333-A1 | Type b botulism toxin inhibitors | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2004-09-09 | — | — | US | disclosed |
| US-20020091142-A1 | Alpha4beta1 and alpha4beta7 integrin inhibitors | COOKE NIGEL GRAHAM (US) | 2002-07-11 | — | — | US | disclosed |
| WO-2001068586-A2 | α4β1 AND α4β7 INTEGRIN INHIBITORS | NOVARTIS AG (CH) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091142-A1 | Alpha4beta1 and alpha4beta7 integrin inhibitors | ITGB1, ITGB4, ITGB7 | ACE 3313/4885ITGB3 11/4885ITGA2B 7/4885 |
| US-20040176333-A1 | Type b botulism toxin inhibitors | GZMB, CFB, MAOB | ACE 868/4885ITGB3 2381/4885ITGA2B 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.